Document Classification

Section Type: RESULTS

Text: At median follow-up of 61. 7 months, patients receiving rapidly cycled tandem high-dose therapy (HD ; two cycles [2x] epirubicin 90 mg/m (2) and cyclophosphamide 600 mg/m (2) every 14 days, followed by 2x epirubicin 90 mg/m (2), cyclophosphamide 3, 000 mg/m (2), and thiotepa 400 mg/m (2) every 21 days) had better disease-free survival (DFS ; hazard ratio [HR] = 0. 62 ; 95 % CI, 0. 44 to 0. 89) and overall survival (OS ; HR = 0. 59 ; 95 % CI, 0. 4 to 0. 89) than those receiving conventional dose-dense chemotherapy (DD ; 4x epirubicin 90 mg/m (2) and cyclophosphamide 600 mg/m (2), followed by 3x cyclophosphamide 600 mg/m (2), methotrexate 40 mg/m (2), and fluorouracil 600 mg/m (2) every 14 days).